LFWD secures FDA clearance for its ReWalk 7 Exoskeleton, introducing enhanced features to empower individuals with spinal cord injury and expand mobility options.

Lifeward stock is trading higher on Thursday after the company announced that its ReWalk 7 received 510(k) clearance from the ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a ...

Last week, Lifeward said full-year revenue rose to $25.7 million from $13.9 million. It said ReWalk Personal Exoskeleton sales increased by 130% in 2024, fueled by recently established Medicare ...

Lifeward announced today that it received FDA 510(k) clearance for its latest-generation personal exoskeleton device, ReWalk ...

FDA clearance for the newest generation of its personal exoskeleton device, the ReWalk 7. The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury ...

CorLife, a division of Numotion, has become the exclusive distributor for Lifeward’s ReWalk Personal Exoskeleton for people with workers’ compensation claims.

Lifeward Ltd. LFWD recently announced that it has received FDA 510(k) clearance for its latest innovation, the ReWalk 7 Exoskeleton. This next-generation wearable device is designed to help ...

The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury (SCI) to stand and walk again, includes a number of new features, as well as ...